Sign in
Taking people in United StatesPhase 4

The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic Pain and PTSD

Key facts

Who runs it
Margaux M. Salas, PhD
Where
San Antonio, United StatesSee the site
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
30 people, planned
Started
2 Oct 2024
Expected to end
May 2027
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Ketamine
  • Magnesium sulfate
  • Ketamine + Magnesium sulfate
Record updated
25 February 2025

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 28 criteriaShow less

Who can take part

  • 18-70 years old with Chronic Neuropathic Pain >= 3 months
  • Biologic male or biologic female
  • Women of childbearing age will be included if there are no plans of pregnancy within the study period, the participant agrees to actively utilize contraception throughout the study, and agrees to pregnancy tests
  • Active Duty, Veterans, and retirees
  • Ketamine naïve for 1 year
  • Moderate Neuropathic pain Scale 4-7

Who cannot take part

  • History of recent heart attack, vascular disease, or any other medical condition that may be deemed by a provider as a contraindication to receiving ketamine
  • Patients who are not able to abide by the pre-treatment and posttreatment clinical protocol, such as food intake, abstaining from certain medications, unable to remain in the clinic for a minimum of 1 hour for observation, and cannot provide the name and phone number of the party who will pick them up post-treatment
  • Psychiatric illness involving psychosis
  • Neurocognitive disorder
  • Acute cardiovascular disease or poorly controlled hypertension
  • Untreated or uncontrolled thyroid disease
  • Severe liver or renal disease
  • Renal impairment
  • Elevated Blood Pressure/hypertension
  • Known hypersensitivity to Ketamine
  • A history of drug abuse or dependence
  • Cognitive dysfunction
  • Patients with Traumatic Brain Injury (TBI)
  • Hyperthyroidism
  • Active substance abuse
  • Pregnant or lactating
  • Patients who are planning to become pregnant within 12 weeks of treatment completion
  • Hemodynamic instability
  • Respiratory depression
  • Use of Theophylline or Aminophylline, Sympathomimetics and Vasopressin,
  • Use of Benzodiazepines
  • Active risk of substance use

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

This trial is currently available in United States.

  • Brooke Army Medical CenterSan Antonio, United StatesContact: Kevin Peterson, MDTaking people

About the trial

What the trial wants to find out

This study is aimed to evaluate outpatient ketamine infusion within a military chronic neuropathic pain population and its effect on PTSD. Currently, this is a pilot study with 30 participants. Participants will be randomized to (1) a moderate dose ketamine, (2) moderate dose ketamine +Mg, or (3) a magnesium control group. Participants will complete self-reported pain and PTSD questionnaires throughout the ~24-week study period. The outlined strategy will provide evidence for the utility of ketamine in neuropathic pain management and pain associated comorbidities within a military population.

The 3 groups in the trial

  • Moderate Dose KetamineTreatment being tested

    0.5 mg/kg/hr The total amount of ketamine for each participant is dependent on their body weight in kg per ideal body weight (IBW) formula. This total ketamine dose will be injected into one 250 ml normal saline 0.9% solution with a rate of 62.5 ml/hr over four hours or until the contents of the bag are infused and flushed with 20 ml of normal saline

    Treatment: Ketamine

  • Moderate dose ketamine + magnesium sulfateTreatment being tested

    0.50 mg/kg/hr ketamine + 750 mg/hr Mg

    Treatment: Ketamine + Magnesium sulfate

  • Magnesium sulfateExisting treatment, for comparison

    750 mg/hr

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic Pain and PTSD: A Prospective Randomized Design
Criteria questions
Built from NCT06414356, who can take part
Record updated
25 February 2025